AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15267080 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study 10673253 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blockers
Number of subjects: 869
Study 9085324 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-of-four (TOF) dosing of vecuronium
Number of subjects: 20
Study 9085324 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical assessment dosing of vecuronium
Number of subjects: 20
Study 8435994 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care
Number of subjects: 206
Study 8435994 — intervention group
Group type: COMPARATOR
Intervention: General practitioner care
Number of subjects: 206
Study 8435994 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinic care
Number of subjects: 206
Study 30137217 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg)
Number of subjects: 16
Study 30137217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 27163498 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release gastroresistant formulation of ketoprofen under fed conditions
Number of subjects: 16
Study 27163498 — intervention group
Group type: COMPARATOR
Intervention: Delayed-release gastroresistant formulation of ketoprofen under fasting conditions
Number of subjects: 16
Study 27163498 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of Cmax/AUC between sexes
Number of subjects: 16
Study 24445100 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted screening and education intervention by general practitioners, including skin examination and counseling with information leaflets.
Number of subjects: 173
Study 24445100 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted screening and education intervention by general practitioners.
Number of subjects: 173
Study 22781424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) for patients with LBBB
Number of subjects: 610
Study 22781424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) for patients without LBBB
Number of subjects: 610
Study 22781424 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in QRS duration with CRT pacing
Number of subjects: 610
Study 22781424 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration
Number of subjects: 610
Study 20159726 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV therapy
Number of subjects: 50
Study 20159726 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 50
Study 18316137 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg/day
Number of subjects: 100
Study 18316137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 16062002 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical practice guidelines for fracture prevention and osteoporosis management
Number of subjects: 0
Study 16062002 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance and education for public health nurses and nutritionists
Number of subjects: 0
Study 16062002 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive measures against fractures and osteoporosis
Number of subjects: 0
Study 12814146 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 7-10 days
Number of subjects: 1373
Study 12814146 — intervention group
Group type: COMPARATOR
Intervention: Comparator antibacterials (amoxicillin 1000 mg three-times daily, clarithromycin 500 mg twice daily, trovafloxacin 200 mg once daily)
Number of subjects: 1373
Study 10583454 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal jejunal feeding
Number of subjects: 8
Study 10583454 — intervention group
Group type: COMPARATOR
Intervention: Distal jejunal feeding
Number of subjects: 8
Study 8607489 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with omeprazole 20 mg b.i.d. plus amoxicillin 1 g b.i.d. and azithromycin 500 mg mane (for the first 3 days)
Number of subjects: 92
Study 8607489 — intervention group
Group type: COMPARATOR
Intervention: Double therapy with omeprazole 20 mg b.i.d. plus amoxicillin 1 g t.i.d.
Number of subjects: 92
Study 8607489 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 92
Study 8607489 — intervention group
Group type: COMPARATOR
Intervention: Double therapy
Number of subjects: 92
Study 1898142 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium therapy (178 mEq over the first 4 postoperative days)
Number of subjects: 99
Study 1898142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 6359047 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidarabine 15 mg/kg/d
Number of subjects: 39
Study 6359047 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidarabine 30 mg/kg/d
Number of subjects: 39
Study 6359047 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidarabine (both dosages)
Number of subjects: 39
Study 6359047 — intervention group
Group type: COMPARATOR
Intervention: Control group from prior trial
Number of subjects: 39
Study 31589553 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Resistance (IR) prevalence measurement
Number of subjects: 230
Study 31589553 — intervention group
Group type: EXPERIMENTAL
Intervention: Body fat percentage measurement
Number of subjects: 230
Study 31589553 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of Type 2 diabetes mellitus (T2DM)
Number of subjects: 230
Study 31589553 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 230
Study 31589553 — intervention group
Group type: EXPERIMENTAL
Intervention: Edema
Number of subjects: 230
Study 31589553 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinuria
Number of subjects: 230
Study 29401328 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment under ACC/AHA guidelines
Number of subjects: 1000
Study 27066779 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer tailored intervention for physical activity action planning
Number of subjects: 346
Study 27066779 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer tailored intervention for fruit and vegetable action planning
Number of subjects: 346
Study 27066779 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer tailored intervention
Number of subjects: 346
Study 24381222 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS)
Number of subjects: 1926
Study 24381222 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in maternal log TfR
Number of subjects: 1926
Study 24381222 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in maternal hemoglobin
Number of subjects: 1926
Study 24381222 — intervention group
Group type: COMPARATOR
Intervention: No LNS
Number of subjects: 1926
Study 23153188 — intervention group
Group type: EXPERIMENTAL
Intervention: C-seal
Number of subjects: 616
Study 23153188 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 616
Study 20216022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance for upper extremity blocks
Number of subjects: 24
Study 20216022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance for lower extremity blocks
Number of subjects: 24
Study 17595230 — intervention group
Group type: EXPERIMENTAL
Intervention: 6948 lead (6.6 Fr. Sprint Fidelis)
Number of subjects: 159
Study 17595230 — intervention group
Group type: EXPERIMENTAL
Intervention: 6949 lead (6.6 Fr. Sprint Fidelis)
Number of subjects: 159
Study 17595230 — intervention group
Group type: COMPARATOR
Intervention: Larger leads (Models 6942, 6943, 6944, 6947, and 4074)
Number of subjects: 159
Study 16281429 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIg)
Number of subjects: 160
Study 16281429 — intervention group
Group type: COMPARATOR
Intervention: Plasmapheresis
Number of subjects: 160
Study 16281429 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian normal-normal model
Number of subjects: 160
Study 12002292 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilation and curettage (D & C)
Number of subjects: 131
Study 12002292 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin‐releasing hormone analogue (GnRHa) for 1 month
Number of subjects: 131
Study 12002292 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin‐releasing hormone analogue (GnRHa) for 3 months
Number of subjects: 131
Study 12002292 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol for 3 months
Number of subjects: 131
Study 12002292 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 15 mg for 3 months
Number of subjects: 131
Study 9653613 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose lispro before dinner (20% reduction) and increased NPH at bedtime (125% of usual dose)
Number of subjects: 13
Study 9653613 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual-dose lispro plus usual-dose NPH before dinner
Number of subjects: 13
Study 9653613 — intervention group
Group type: COMPARATOR
Intervention: Standard premeal human regular insulin and pre-bedtime NPH insulin (control)
Number of subjects: 13
Study 8593015 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg oral valaciclovir
Number of subjects: 12
Study 8593015 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg [14C]valaciclovir
Number of subjects: 12
Study 2569686 — intervention group
Group type: EXPERIMENTAL
Intervention: OKY-046 80 mg (L group)
Number of subjects: 0
Study 2569686 — intervention group
Group type: EXPERIMENTAL
Intervention: OKY-046 400 mg (H group)
Number of subjects: 0
Study 2569686 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P group)
Number of subjects: 0
Study 1090417 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate cream
Number of subjects: 34
Study 1090417 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate ointment
Number of subjects: 34
Study 31171523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin
Number of subjects: 675
Study 31171523 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin
Number of subjects: 675
Study 31171523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin (large artery atherosclerosis)
Number of subjects: 675
Study 31171523 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin (large artery atherosclerosis)
Number of subjects: 675
Study 28427362 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy (MRT)
Number of subjects: 1239
Study 28427362 — intervention group
Group type: COMPARATOR
Intervention: Higher, fixed-dose budesonide plus as-needed terbutaline
Number of subjects: 1239
Study 26301864 — intervention group
Group type: EXPERIMENTAL
Intervention: Connect intervention (Internet-based sessions)
Number of subjects: 193
Study 26301864 — intervention group
Group type: COMPARATOR
Intervention: Control group (general educational video)
Number of subjects: 193
Study 25053261 — intervention group
Group type: EXPERIMENTAL
Intervention: Celebrating the strengths of black youth (CSBY) intervention, consisting of 10 in-person group sessions
Number of subjects: 73
Study 25053261 — intervention group
Group type: EXPERIMENTAL
Intervention: Celebrating the strengths of black youth (CSBY) intervention
Number of subjects: 73
Study 25053261 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC) group
Number of subjects: 73
Study 22395731 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist (levodopa)
Number of subjects: 53
Study 22395731 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine antagonist (haloperidol)
Number of subjects: 53
Study 22395731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 19157723 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Number of subjects: 854
Study 19157723 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Number of subjects: 854
Study 19157723 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 854
Study 17180268 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized bupivacaine
Number of subjects: 80
Study 17180268 — intervention group
Group type: EXPERIMENTAL
Intervention: Local bupivacaine in the bladder bed
Number of subjects: 80
Study 17180268 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized normal saline
Number of subjects: 80
Study 17180268 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 16087986 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine pyramethamine (SP)
Number of subjects: 141
Study 16087986 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (100,000 or 200,000 IU depending on age)
Number of subjects: 141
Study 12123540 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily
Number of subjects: 12637
Study 12123540 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg daily
Number of subjects: 12637
Study 10201413 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (n=34)
Number of subjects: 78
Study 10201413 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=44)
Number of subjects: 78
Study 7778957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftizoxime sodium (1 g every 12 hours) or ceftriaxone sodium (1 g every 24 hours) followed by oral cefixime (400 mg every 24 hours) after meeting criteria for switch.
Number of subjects: 120
Study 2181111 — intervention group
Group type: EXPERIMENTAL
Intervention: BANA hydrolysis assay
Number of subjects: 117
Study 2181111 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA for antibodies to B. gingivalis and T. denticola
Number of subjects: 117
Study 2181111 — intervention group
Group type: EXPERIMENTAL
Intervention: Reagent card format for BANA hydrolysis
Number of subjects: 117
Study 2181111 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diagnostic procedures (ELISA and BANA hydrolysis)
Number of subjects: 117
Study 7000171 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% acyclovir
Number of subjects: 60
Study 7000171 — intervention group
Group type: COMPARATOR
Intervention: 0.5% idoxuridine (IDU)
Number of subjects: 60
Study 31823309 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-hour integrated curriculum on conflicts of interest and shared decision-making
Number of subjects: 63
Study 31823309 — intervention group
Group type: COMPARATOR
Intervention: Course manual adapted from teaching as usual
Number of subjects: 63
Study 31934993 — intervention group
Group type: EXPERIMENTAL
Intervention: BCD-132 (100 to 1000 mg intravenous infusion)
Number of subjects: 24
Study 28950697 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived barriers towards breast cancer screening
Number of subjects: 816
Study 24237929 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diltiazem cream
Number of subjects: 114
Study 24237929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 23704673 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone (M+R)
Number of subjects: 0
Study 23704673 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone (M)
Number of subjects: 0
Study 23704673 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus lifestyle (M+L)
Number of subjects: 0
Study 23704673 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (M+R, M, M+L)
Number of subjects: 0
Study 23704673 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiposity measures (BMI, waist circumference, abdominal height, fat)
Number of subjects: 0
Study 21585061 — intervention group
Group type: EXPERIMENTAL
Intervention: Pricking bleeding therapy (applied to specific points on the thumb and auricular helix), once daily for 7 days.
Number of subjects: 60
Study 21585061 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic atomizing inhalation (UAI), once daily for 7 days for 15 minutes.
Number of subjects: 60
Study 21585061 — intervention group
Group type: EXPERIMENTAL
Intervention: Pricking bleeding therapy
Number of subjects: 60
Study 21585061 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic atomizing inhalation (UAI)
Number of subjects: 60
Study 21585061 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 19532041 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (add-on treatment)
Number of subjects: 0
Study 19532041 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy antiepileptic drugs (head-to-head trials)
Number of subjects: 0
Study 19532041 — intervention group
Group type: COMPARATOR
Intervention: Pseudoplacebo
Number of subjects: 0
Study 16904458 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alprostadil cream 100 microg
Number of subjects: 1732
Study 16904458 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alprostadil cream 200 microg
Number of subjects: 1732
Study 16904458 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alprostadil cream 300 microg
Number of subjects: 1732
Study 16904458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1732
Study 16904458 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alprostadil cream (all doses)
Number of subjects: 1732
Study 14990632 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg/d
Number of subjects: 1093
Study 14990632 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg/d
Number of subjects: 1093
Study 14990632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1093
Study 10619583 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan (50 mg)
Number of subjects: 12
Study 10619583 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan (80 mg)
Number of subjects: 12
Study 10619583 — intervention group
Group type: EXPERIMENTAL
Intervention: irbesartan (150 mg)
Number of subjects: 12
Study 10619583 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 7488395 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaporimeter
Number of subjects: 0
Study 7488395 — intervention group
Group type: EXPERIMENTAL
Intervention: Tewameter
Number of subjects: 0
Study 2042654 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate, 950 mg four times a day
Number of subjects: 8
Study 2042654 — intervention group
Group type: COMPARATOR
Intervention: Aluminum hydroxide (2.4 g/d)
Number of subjects: 8
Study 7200859 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristin, adriamycin and cis‐platinum (n = 21)
Number of subjects: 43
Study 7200859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide and cis‐platinum (n = 22)
Number of subjects: 43
Study 7200859 — intervention group
Group type: COMPARATOR
Intervention: Ifosfamide and cis‐platinum
Number of subjects: 43
Study 31451360 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered web-based decision aid
Number of subjects: 2702
Study 30843441 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous embolisation (with or without transarterial embolisation)
Number of subjects: 76
Study 30843441 — intervention group
Group type: COMPARATOR
Intervention: Transarterial embolisation alone
Number of subjects: 76
Study 30843441 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous embolisation
Number of subjects: 76
Study 29063521 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) for 8 weeks
Number of subjects: 80
Study 29063521 — intervention group
Group type: COMPARATOR
Intervention: Health enhancement program (HEP)
Number of subjects: 80
Study 29063521 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline amygdala activation
Number of subjects: 80
Study 29063521 — intervention group
Group type: COMPARATOR
Intervention: MBCT and HEP
Number of subjects: 80
Study 24216046 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training seven times per week for at least 2 weeks before surgery
Number of subjects: 0
Study 23148822 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity exercise intervention (ST+EX)
Number of subjects: 150
Study 23148822 — intervention group
Group type: COMPARATOR
Intervention: Health and wellness education intervention (ST+CTRL)
Number of subjects: 150
Study 20600693 — intervention group
Group type: EXPERIMENTAL
Intervention: Click train
Number of subjects: 0
Study 17585210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at a concentration of 2.0% maintained for at least 10 min, with adjustments based on patient movement (6-8% induction, 100% oxygen).
Number of subjects: 90
Study 16130190 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg mycophenolate mofetil (MMF) twice daily
Number of subjects: 0
Study 16130190 — intervention group
Group type: COMPARATOR
Intervention: FK506
Number of subjects: 0
Study 16130190 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 0
Study 16130190 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA
Number of subjects: 0
Study 12165821 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated and humidified gas
Number of subjects: 20
Study 12165821 — intervention group
Group type: COMPARATOR
Intervention: Standard carbon dioxide (CO2) gas (control)
Number of subjects: 20
Study 10434353 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone alone
Number of subjects: 0
Study 10434353 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan-dexamethasone
Number of subjects: 0
Study 10434353 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone-interferon alpha
Number of subjects: 0
Study 10434353 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 10434353 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8537029 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% tropicamide with nasolacrimal occlusion
Number of subjects: 40
Study 8537029 — intervention group
Group type: COMPARATOR
Intervention: 0.125% tropicamide without nasolacrimal occlusion
Number of subjects: 40
Study 2209407 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 479
Study 2209407 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 479
Study 6218098 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin treatment
Number of subjects: 58
Study 6218098 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58